These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16426329)

  • 1. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome.
    Oyen O; Strøm EH; Midtvedt K; Bentdal O; Hartmann A; Bergan S; Pfeffer P; Brekke IB
    Am J Transplant; 2006 Feb; 6(2):412-8. PubMed ID: 16426329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postrenal transplant hemolytic uremic syndrome/thrombotic microangiopathy: Ahmedabad experience.
    Goplani KR; Vanikar AV; Shah PR; Gumber M; Feroz A; Patel HV; Kasat P; Falodia J; Saboo D; Kaswaan K; Geerish MS; Pandya T; Trivedi HL
    Transplant Proc; 2008 May; 40(4):1114-6. PubMed ID: 18555127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival.
    Caires RA; Marques ID; Repizo LP; Sato VA; Carmo LP; Machado DJ; de Paula FJ; Nahas WC; David-Neto E
    Transplant Proc; 2012 Oct; 44(8):2388-90. PubMed ID: 23026601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy.
    Schwimmer J; Nadasdy TA; Spitalnik PF; Kaplan KL; Zand MS
    Am J Kidney Dis; 2003 Feb; 41(2):471-9. PubMed ID: 12552512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved 24-hour blood pressure control with sirolimus versus calcineurin inhibitor based immunosuppression in renal transplant recipients.
    Steigerwalt SP; Brar N; Dhungel A; Butcher D; Steigerwalt S; El-Ghouroury M; Provenzano R
    Transplant Proc; 2009 Dec; 41(10):4184-7. PubMed ID: 20005365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. De novo hemolytic-uremic syndrome/thrombotic microangiopathy in renal transplant patients receiving calcineurin inhibitors: role of sirolimus.
    Franco A; Hernandez D; Capdevilla L; Errasti P; Gonzalez M; Ruiz JC; Sanchez J;
    Transplant Proc; 2003 Aug; 35(5):1764-6. PubMed ID: 12962787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A calcineurin inhibitor-sparing regimen with sirolimus, mycophenolate mofetil, and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function.
    Chang GJ; Mahanty HD; Vincenti F; Freise CE; Roberts JP; Ascher NL; Stock PG; Hirose R
    Clin Transplant; 2000 Dec; 14(6):550-4. PubMed ID: 11127307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulminant recurrence of atypical hemolytic uremic syndrome during a calcineurin inhibitor-free immunosuppression regimen.
    Florman S; Benchimol C; Lieberman K; Burrows L; Bromberg JS
    Pediatr Transplant; 2002 Aug; 6(4):352-5. PubMed ID: 12234280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and early resumption of cyclosporin A in renal allograft recipients with thrombotic microangiopathy and hemolytic uremic syndrome.
    Wiener Y; Nakhleh RE; Lee MW; Escobar FS; Venkat KK; Kupin WL; Mozes MF
    Clin Transplant; 1997 Jun; 11(3):157-62. PubMed ID: 9193835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttransplant hemolytic uremic syndrome in adult retransplanted kidney graft recipients: advantage of FK506 therapy?
    Franz M; Regele H; Schmaldienst S; Stummvoll HK; Hörl WH; Pohanka E
    Transplantation; 1998 Nov; 66(9):1258-62. PubMed ID: 9825827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy.
    Bren A; Pajek J; Grego K; Buturovic J; Ponikvar R; Lindic J; Knap B; Vizjak A; Ferluga D; Kandus A
    Transplant Proc; 2005 May; 37(4):1889-91. PubMed ID: 15919494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Posttransplantation calcineurin inhibitor-induced hemolytic uremic syndrome: single-center experience.
    Said T; Al-Otaibi T; Al-Wahaib S; Francis I; Nair MP; Halim MA; El-Sayed A; Nampoory MR
    Transplant Proc; 2010 Apr; 42(3):814-6. PubMed ID: 20430179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation.
    Nava F; Cappelli G; Mori G; Granito M; Magnoni G; Botta C; Solazzo A; Fontana F; Baisi A; Bonucchi D
    Transplant Proc; 2014 Sep; 46(7):2263-8. PubMed ID: 25242766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo sirolimus-based regimen in Thai renal transplant recipients.
    Townamchai N; Avihingsanon Y; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
    Transplant Proc; 2008 Sep; 40(7):2206-8. PubMed ID: 18790193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections.
    Artz MA; Steenbergen EJ; Hoitsma AJ; Monnens LA; Wetzels JF
    Transplantation; 2003 Sep; 76(5):821-6. PubMed ID: 14501861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A favorable 3-year outcome of kidney transplantation in atypical hemolytic uremic syndrome associated with a factor H mutation: case report.
    Albertazzi V; Bonucchi D; De Amicis S; Americo C; Ghiandai G; Cappelli G
    Transplant Proc; 2010 May; 42(4):1352-4. PubMed ID: 20534299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
    Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to sirolimus in pediatric renal transplantation recipients.
    Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
    Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.